Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 ...

Some might describe Johnson & Johnson's business as boring, but sometimes, that's not such a bad thing. Selling pharmaceutical products is a steady and reliable business even when the economy is ...